Morgan Stanley lowered the firm’s price target on Stride (LRN) to $130 from $159 and keeps an Equal Weight rating on the shares. Stride posted a relatively in-line fiscal Q1, but headwinds are expected to disrupt Stride’s enrollment throughout the ’25/’26 school year, notes the analyst, who is lowering the firm’s FY26 revenue and adjusted operating income estimates by 7% and 12%, respectively.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRN:
- Stride price target lowered to $125 from $175 at Canaccord
- Stride’s Long-Term Potential Remains Intact Despite Short-Term Challenges
- Stride downgraded to Market Perform from Outperform at BMO Capital
- BMO downgrades Stride on ‘disappointing’ fiscal 2026 outlook
- Stride, Inc. Reports Strong Q1 2026 Financial Growth